141286-68-2

Upstream product

• 151389-59-2 2-(4-chlorobenzenesulfonylamino)ethyl bromide 
• 141286-92-2 (2,6-difluoro-4-mercaptophenoxy)acetic acid methyl ester 
• 28177-48-2 2,6-difluorophenol 
• 152677-78-6 (4-chlorosulfonyl-2,6-difluorophenoxy)acetic acid methyl ester 
• 4875-54-1 4-chloro-benzenesulfonic acid-(2-chloro-ethylamide) 
• 141286-91-1 (2,6-difluorophenoxy)acetic acid methyl ester 

Downstream Products

• 169298-45-7 methyl 4-<2-amino>ethylthio>-2,6-difluorophenoxyacetate 
• 151389-32-1 methyl 4-<2-aminoethylthio>-2,6-difluorophenoxyacetate 
• 169298-37-7 {4-[2-(4-Chloro-benzenesulfonylamino)-ethanesulfinyl]-2,6-difluoro-phenoxy}-acetic acid methyl ester 
• 1026848-78-1 (4-{2-[(4-Chloro-benzenesulfonyl)-pentyl-amino]-ethylsulfanyl}-2,6-difluoro-phenoxy)-acetic acid methyl ester 
• 1026659-62-0 (4-{2-[Benzyl-(4-chloro-benzenesulfonyl)-amino]-ethylsulfanyl}-2,6-difluoro-phenoxy)-acetic acid methyl ester 
• 1026150-42-4 (4-{2-[(4-Chloro-benzenesulfonyl)-pyridin-2-ylmethyl-amino]-ethylsulfanyl}-2,6-difluoro-phenoxy)-acetic acid methyl ester 
• 1026657-72-6 methyl 4-<2-ethylthio>-2,6-difluorophenoxyacetate 
• 169298-38-8 methyl 4-<2-(4-chlorophenylsulfonylamino)ethylsulfonyl>-2,6-difluorophenoxyacetate 

Relevant academic research and scientific papers

GLUTAMIC ACID RECEPTOR AGONIST

A method comprising administering a sulfonamide derivative to a patient requiring activation of glutamate receptors, the sulfonamide derivative represented by the formula STR1 wherein A is a napthyl group, a pyridyl group, a phenyl group, a phenyl group s

Synthesis and evaluation of novel fluorinated sulotroban-related sulfonamide derivatives as thromboxane A2 receptor antagonists

A series of sulotroban-related arylsulfonamide derivatives possessing a fluorinated phenoxyacetic acid moiety was synthesized and tested for TXA2 antagonizing ability on U-46619-induced platelet aggregation of rabbit platelet-rich plasma. Introduction of one or more fluorine atoms to the phenoxyacetic acid moiety increased this activity. The most potent compound among these compounds was 10c, which was 40-fold more potent (IC50 3.4 x 10-7 M) than sulotroban. 10c exhibited high activity (ID50 0.14 mg/kg) against a D-46619-induced acute thrombocytopenia model in mice when orally administrated. These findings and those of radioligand binding assays with various ligands showed 10c to be a potent and selective systemic TXA2 receptor antagonist.